- Home
- PUMP vs FTH Comparison
PUMP vs FTH Comparison
Compare PUMP & FTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PUMP | FTH |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 835.7M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PUMP | FTH |
|---|---|---|
| Price | $10.70 | $344.95 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $14.14 | N/A |
| AVG Volume (30 Days) | ★ 3.7M | 298.6K |
| Earning Date | 04-30-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.76 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,269,158,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $15.61 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.64 | $17.50 |
| 52 Week High | $18.50 | $37.90 |
Technical Indicators
Market Signals| Indicator | PUMP | FTH |
|---|---|---|
| Relative Strength Index (RSI) | 39.67 | 64.64 |
| Support Level | $10.28 | $22.69 |
| Resistance Level | $11.90 | $36.94 |
| Average True Range (ATR) | 0.55 | 3.04 |
| MACD | 0.01 | 0.49 |
| Stochastic Oscillator | 6.36 | 84.47 |
Price Performance
Historical ComparisonAbout PUMP ProPetro Holding Corp.
ProPetro Holding Corp is a Texas-based oilfield services company. It provides hydraulic fracturing, wireline, and other complementary services to oil and gas companies engaged in the exploration and production of North American oil and natural gas resources. The company focused on the Permian Basin. The operating segments of the company are hydraulic fracturing which generates key revenue, wireline, cementing, and power generation service.
About FTH Faeth Therapeutics Inc. Common Stock
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.